Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06126796 · ClinicalTrials.gov registry record
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 107
- Enrollment target
NCT06126796: Completed study, sponsored by Mayo Clinic.
NCT06126796 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06126796 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra.
Primary Outcome
Patient preference will be assessed based on the Preference Questionnaire (PQ) after completion of the study cross-over period (after both methods of testing have been experienced).
Interventions
- DIAGNOSTIC_TEST CxBladder Monitor
- DIAGNOSTIC_TEST Cystoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2025-09-08 |
What the finished NCT06126796 record still lists
NCT06126796 is an observational study that tracks outcomes without assigning an intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which CxBladder Monitor is the first listed.
NCT06126796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06126796 about?
NCT06126796 is a clinical study titled "Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)". The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample f...
What is the current status of trial NCT06126796?
This trial is currently completed. The enrollment target is 107 participants. The study started on 2023-11-16. Estimated completion is 2025-09-08.
What interventions are being tested in trial NCT06126796?
The interventions under investigation include: CxBladder Monitor (DIAGNOSTIC_TEST), Cystoscopy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06126796?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI